ADCT ADC Therapeutics SA

USD 3.82 0.00 0
Icon

ADC Therapeutics SA (ADCT) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NYE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 3.82

0.00 (0.00)%

USD 0.37B

0.48M

USD 9.50(+148.69%)

USD 5.00 (+30.89%)

Icon

ADCT

ADC Therapeutics SA (USD)
COMMON STOCK | NYE
USD 3.82
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.37B

USD 5.00 (+30.89%)

USD 3.82

ADC Therapeutics SA (ADCT) Stock Forecast

Show ratings and price targets of :
USD 9.50
(+148.69%)

Based on the ADC Therapeutics SA stock forecast from 3 analysts, the average analyst target price for ADC Therapeutics SA is USD 9.50 over the next 12 months. ADC Therapeutics SA’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ADC Therapeutics SA is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, ADC Therapeutics SA’s stock price was USD 3.82. ADC Therapeutics SA’s stock price has changed by +17.18% over the past week, +15.76% over the past month and +152.98% over the last year.

No recent analyst target price found for ADC Therapeutics SA
No recent average analyst rating found for ADC Therapeutics SA

Company Overview ADC Therapeutics SA

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated ...Read More

Biopole, Epalinges, Switzerland, 1066

273

September

USD

USA

Adjusted Closing Price for ADC Therapeutics SA (ADCT)

Loading...

Unadjusted Closing Price for ADC Therapeutics SA (ADCT)

Loading...

Share Trading Volume for ADC Therapeutics SA Shares

Loading...

Compare Performance of ADC Therapeutics SA Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ADCT

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To ADC Therapeutics SA (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S 0.00 (0.00%) USD634.05B 49.43 4.92

ETFs Containing ADCT

Symbol Name ADCT's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About ADC Therapeutics SA (ADCT) Stock

Based on ratings from 3 analysts ADC Therapeutics SA's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.

Unfortunately we do not have enough data on ADCT's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for ADCT is USD 9.50 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 8.

ADCT stock's Price/Earning ratio is -99,999.99. Our analysis grades ADCT stock's Price / Earning ratio at B. This means that ADCT stock's Price/Earning ratio is above 14% of the stocks in the Biotechnology sector in the NYE exchange. Based on this ADCT may be undervalued for its sector.

The last closing price of ADCT's stock was USD 3.82.

The most recent market capitalization for ADCT is USD 0.37B.

Based on targets from 3 analysts, the average taret price for ADCT is projected at USD 9.50 over the next 12 months. This means that ADCT's stock price may go up by +148.69% over the next 12 months.

We can't find any ETFs which contains ADC Therapeutics SA's stock.

As per our most recent records ADC Therapeutics SA has 273 Employees.

ADC Therapeutics SA's registered address is Biopole, Epalinges, Switzerland, 1066. You can get more information about it from ADC Therapeutics SA's website at https://www.adctherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...